Донор оксида азота изосорбида динитрат повышает противоопухолевый эффект доксорубицина при химиотерапии экспериментальной глиобластомыстатья
Статья опубликована в журнале из списка RSCI Web of Science
Статья опубликована в журнале из перечня ВАК
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 1 апреля 2022 г.
Аннотация:Alekseeva AI, VV Kudelkina, AM Kosyreva, SF Drozd, SE Gelperina, GV Pavlova, AS Khalansky
Nitric oxide donor nitrosorbide potentiates the antitumor effect of doxorubicin against experimental glioblastoma
ABSTRACTBackground. Doxorubicin is a well-known antitumor drug that is not employed for chemotherapy of brain tumors. Indeed, doxorubicin does not penetrate across the blood-brain barrier in therapeutic concentrations.Objective. To study the antitumor effect of doxorubicin combined with nitrosorbide on intracranial experimental glioblastoma 101/8 in rats.Material and methods. Male Wistar rats (n=86) with intracranial implanted glioblastoma 101/8 received doxorubicin (i.v. 3 х 1.5 mg/kg) alone or in combination with nitrosorbide (i.v or orally, 3 х 0.5 mg/kg) in 2, 5 and 8 days after implantation. Efficacy was assessed considering survival and brain tumor volume in 14 days after tumor implantation.Results. Combination of doxorubicin and nitrosorbide significantly increased survival (57% and 155%, respectively) and slowed down tumor growth (16±12 and 8±6 mm3, respectively) compared to doxorubicin alone. Effectiveness of nitrosorbide alone was trivial.Conclusion. Nitric oxide donor nitrosorbide considerably potentiated the antitumor effect of doxorubicin against intracranial 101/8 glioblastoma in rats.